Loading...
XNAS
MRNA
Market cap10bUSD
Jun 06, Last price  
27.46USD
1D
5.13%
1Q
-22.89%
IPO
46.06%
Name

Moderna Inc

Chart & Performance

D1W1MN
P/E
P/S
3.28
EPS
Div Yield, %
Shrs. gr., 5y
3.03%
Rev. gr., 5y
132.11%
Revenues
3.24b
-52.75%
101,536,000176,974,000122,512,00048,036,000274,490,00017,736,000,00019,263,000,0006,848,000,0003,236,000,000
Net income
-3.56b
L-24.46%
-216,211,000-255,916,000-384,734,000-514,021,000-747,064,00012,202,000,0008,362,000,000-4,714,000,000-3,561,000,000
CFO
-3.00b
L-3.66%
66,734,000-331,484,000-330,865,000-458,968,0002,026,971,00013,620,000,0004,981,000,000-3,118,000,000-3,004,000,000
Earnings
Jul 30, 2025

Profile

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
IPO date
Dec 07, 2018
Employees
3,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
3,236,000
-52.75%
6,848,000
-64.45%
19,263,000
8.61%
Cost of revenue
6,007,000
11,087,000
9,843,000
Unusual Expense (Income)
NOPBT
(2,771,000)
(4,239,000)
9,420,000
NOPBT Margin
48.90%
Operating Taxes
(46,000)
772,000
1,213,000
Tax Rate
12.88%
NOPAT
(2,725,000)
(5,011,000)
8,207,000
Net income
(3,561,000)
-24.46%
(4,714,000)
-156.37%
8,362,000
-31.47%
Dividends
Dividend yield
Proceeds from repurchase of equity
66,000
(1,107,000)
(3,264,000)
BB yield
-0.41%
2.91%
4.37%
Debt
Debt current
25,000
196,000
Long-term debt
1,420,000
2,461,000
2,008,000
Deferred revenue
83,000
673,000
Other long-term liabilities
325,000
256,000
(94,000)
Net debt
(3,015,000)
(10,861,000)
(16,016,000)
Cash flow
Cash from operating activities
(3,004,000)
(3,118,000)
4,981,000
CAPEX
(1,051,000)
(707,000)
(400,000)
Cash from investing activities
1,949,000
4,206,000
(5,176,000)
Cash from financing activities
56,000
(1,377,000)
(3,448,000)
FCF
(6,991,000)
(5,530,000)
7,451,000
Balance
Cash
1,927,000
8,604,000
9,902,000
Long term investments
2,508,000
4,743,000
8,318,000
Excess cash
4,273,200
13,004,600
17,256,850
Stockholders' equity
10,035,000
13,483,000
17,950,000
Invested Capital
7,662,800
2,431,400
3,597,150
ROIC
196.83%
ROCE
44.68%
EV
Common stock shares outstanding
384,000
382,000
416,000
Price
41.58
-58.19%
99.45
-44.63%
179.62
-29.28%
Market cap
15,966,720
-57.97%
37,989,900
-49.16%
74,721,920
-31.74%
EV
12,951,720
27,128,900
58,705,920
EBITDA
(2,582,000)
(3,618,000)
9,768,000
EV/EBITDA
6.01
Interest
24,000
38,000
29,000
Interest/NOPBT
0.31%